NON-INVASIVE BIOMARKERS FOR EARLY DETECTION OF OVARIAN AND ENDOMETRIAL DISORDERS

Abstract

Ovarian and endometrial disorders, including ovarian cancer, endometrial cancer, and endometriosis, remain significant challenges in women’s health due to their late diagnosis and limited availability of reliable early detection methods. Conventional diagnostic techniques such as transvaginal ultrasound, serum CA-125 testing, and histopathology, while valuable, are either invasive, lack specificity, or are effective only in later disease stages. The demand for non-invasive biomarkers has therefore increased, aiming to provide accurate, accessible, and early diagnostic tools that can improve clinical outcomes and reduce mortality rates. Non-invasive biomarkers are measurable biological molecules found in easily obtainable samples such as blood, urine, saliva, or vaginal fluid. Recent research has highlighted the potential of circulating tumor DNA (ctDNA), microRNAs (miRNAs), exosomes, and metabolomic profiles in identifying early disease-related changes. For instance, circulating miRNAs have demonstrated strong associations with both ovarian and endometrial malignancies, offering higher sensitivity than traditional markers. Similarly, metabolomic alterations detectable in serum and urine have shown distinct patterns that differentiate diseased from healthy individuals, suggesting their role in non-invasive diagnostics. In ovarian disorders, especially ovarian cancer, novel biomarker panels combining CA-125 with miRNA or exosome signatures have improved sensitivity and specificity in early-stage detection. In the context of endometrial disorders, non-invasive approaches such as analysis of circulating cell-free DNA methylation and urine-based proteomic markers are emerging as promising tools. These biomarkers not only provide diagnostic value but also support disease monitoring and prognosis prediction. The integration of multi-omics approaches—where genomics, transcriptomics, and metabolomics are combined—has further strengthened the diagnostic landscape by offering comprehensive disease profiles. Despite these advancements, several challenges remain before non-invasive biomarkers can be widely adopted in clinical practice. Issues such as small cohort sizes, lack of standardized methodologies, and variations in patient populations limit reproducibility and generalizability. Large-scale validation studies and standardized protocols are essential to ensure their reliability. Moreover, ethical considerations, cost-effectiveness, and accessibility must be addressed, especially for widespread use in low-resource settings. Overall, the development of non-invasive biomarkers represents a transformative shift in the early detection of ovarian and endometrial disorders. These advances promise to enhance early intervention, reduce diagnostic delays, and improve survival outcomes for women worldwide. With continued interdisciplinary collaboration and validation, non-invasive biomarkers have the potential to transition from research tools into routine clinical diagnostics.